HSKA

Heska Corporation

NASDAQ

Add Alert

HSKA

Heska Corporation

NASDAQ

Add Alert

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

DeafTrader2 PremiumMember

08/03/17 11:27 AM

Post #36

Re: #35: @DeafTrader2 - SICK PUPPY DOWN FALL !

SICK PUPPY DOWN FALL

DeafTrader2 PremiumMember

05/02/17 1:01 PM

Post #35

Re: #33: @coachjim - Nice run up last few days

SICK PUPPY DOWN FALL !

joelawyer

04/25/17 10:54 AM

Post #34

Re: #33: @coachjim - Nice run up last few days

yes, indeed, there has been smile

coachjim

04/25/17 10:07 AM

Post #33

Nice run up last few days

TheFinalCD PremiumMember

10/15/16 2:42 PM

Post #32

Re: #30: @stocktrademan - HSKA bullish 54.85

what a sweet run from mid $20's

Trueheart

10/09/16 1:10 PM

Post #31

Re: #30: @stocktrademan - HSKA bullish 54.85

Thanks for the informative post.

Trueheart

stocktrademan Free

10/09/16 11:55 AM

Post #30

Re: #28: @stocktrademan - $HSKA recent news/filings

HSKA bullish 54.85

bull flag

normal chart

log chart

Trueheart

06/30/16 3:14 PM

Post #29

Last three months have been great!

Trueheart

stocktrademan Free

12/15/15 3:50 PM

Post #28

$HSKA recent news/filings

bullish 35.74

## source: finance.yahoo.com

Fri, 11 Dec 2015 13:34:01 GMT ~ Should Heska Corporation (HSKA) Be On Your Radar Now?

read full: http://finance.yahoo.com/news/heska-corporation-hska-radar-now-133401356.html
*********************************************************

Tue, 08 Dec 2015 18:18:11 GMT ~ HESKA CORP Financials

read full: http://finance.yahoo.com/q/is?s=hska
*********************************************************

Mon, 07 Dec 2015 13:20:00 GMT ~ A Look Inside the Chart, Technical Insights - Research on Trupanion, Tobira Therapeutics, Old Second Bancorp and Heska

[Accesswire] - NEW YORK, NY / ACCESSWIRE / December 7, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trupanion ...

read full: http://finance.yahoo.com/news/look-inside-chart-technical-insights-132000863.html
*********************************************************

Tue, 01 Dec 2015 22:20:30 GMT ~ Do Hedge Funds Love Rocket Fuel Inc (FUEL)?

read full: http://www.insidermonkey.com/blog/do-hedge-funds-love-rocket-fuel-inc-fuel-392977/
*********************************************************

Fri, 27 Nov 2015 13:15:00 GMT ~ A Look Inside the Chart, Technical Insights - Research on Trupanion, Tobira Therapeutics, Old Second Bancorp, and Heska

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 27, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trupanion ...

read full: http://finance.yahoo.com/news/look-inside-chart-technical-insights-131500468.html
*********************************************************

$HSKA charts

basic chart ## source: stockcharts.com

basic chart ## source: stockscores.com

big daily chart ## source: stockcharts.com

big weekly chart ## source: stockcharts.com

$HSKA company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/HSKA/company-info
Ticker: $HSKA
OTC Market Place: Not Available
CIK code: 0001038133
Company name: Heska Corp.
Company website: http://www.heska.com
Incorporated In: DE, USA

Business Description:

$HSKA share structure

## source: otcmarkets.com

Market Value: $227,060,248 a/o Dec 14, 2015
Shares Outstanding: 6,589,096 a/o Nov 13, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$HSKA extra dd links

Company name: Heska Corp.
Company website: http://www.heska.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=HSKA+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=HSKA+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=HSKA+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/HSKA/news - http://finance.yahoo.com/q/h?s=HSKA+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/HSKA/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/HSKA/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=HSKA+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/HSKA
DTCC (dtcc.com): http://search2.dtcc.com/?q=Heska+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Heska+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Heska+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.heska.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.heska.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.heska.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/HSKA
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001038133&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/HSKA/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/HSKA/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=HSKA&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=HSKA
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/HSKA/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=HSKA+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=HSKA+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=HSKA
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=HSKA
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=HSKA+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/HSKA/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=HSKA+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/HSKA.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=HSKA
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/HSKA/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/HSKA/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/HSKA
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/HSKA
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/HSKA:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=HSKA
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=HSKA

$HSKA DD Notes ~ http://www.ddnotesmaker.com/HSKA

stocktrademan Free

05/04/14 7:12 PM

Post #27

bullish double the money by summertime on margin

Penny Roger$ Free

08/29/13 8:44 PM

Post #26

cushsix

05/14/12 9:29 AM

Post #25

NEW YORK (TheStreet) -- Heska Corporation (Nasdaq:HSKA) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:

46.50% is the gross profit margin for HESKA CORP which we consider to be strong. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, HSKA's net profit margin of 3.00% significantly trails the industry average.
Compared to its closing price of one year ago, HSKA's share price has jumped by 50.96%, exceeding the performance of the broader market during that same time frame. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
HESKA CORP's earnings per share declined by 35.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, HESKA CORP turned its bottom line around by earning $0.40 versus -$0.05 in the prior year. This year, the market expects an improvement in earnings ($0.68 versus $0.40).
Regardless of the drop in revenue, the company managed to outperform against the industry average of 5.3%. Since the same quarter one year prior, revenues slightly dropped by 1.7%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Pharmaceuticals industry and the overall market, HESKA CORP's return on equity significantly trails that of both the industry average and the S&P 500.

airbus300

12/29/10 8:22 PM

Post #24

40 cents after hours. Reverse split in the morning.

December 29, 2010 5:00 PM ET
Heska Corporation Announces Stockholder Approval of Reverse Split
PR Newswire

LOVELAND, Colo., Dec. 29, 2010

LOVELAND, Colo., Dec. 29, 2010 /PRNewswire-FirstCall/ -- Heska Corporation HSKA ("Heska" or the "Company") today announced that, at the Company's Special Meeting of Stockholders held on December 29, 2010, the stockholders of Heska voted to approve a proposal to effect a 1-for-10 reverse stock split of the Company's issued and outstanding shares of common stock, together with a corresponding reduction in the total number of shares of the Company's authorized stock and increase in the par value for such authorized stock (collectively, the "Reverse Split"). In connection with the Reverse Split, each stockholder will receive one share of common stock for every ten shares of common stock held prior to the Reverse Split and, if applicable, cash in lieu of any fractional shares that would otherwise be issued in connection with the Reverse Split.

The Reverse Split is intended to be effective and consummated by the Company prior to the commencement of trading on December 30, 2010, as a result of the filing of an amendment to the Company's Certificate of Incorporation (the "Charter Amendment") with the Secretary of State of the State of Delaware.

The Charter Amendment will reduce the number of shares of common stock issued and outstanding from approximately 52.2 million shares to approximately 5.2 million shares. In addition, the Charter Amendment will reduce the total number of authorized shares of the Company's stock from 175,000,000 to 17,500,000, with such reduced number comprising (i) 7,500,000 shares of Common Stock, $0.01 par value per share, (ii) 7,500,000 shares of Public Common Stock, $0.01 par value per share, and (iii) 2,500,000 shares of Preferred Stock, $0.01 par value per share. The Company expects the post-Reverse Split shares of its common stock to begin trading on The NASDAQ Capital Market on December 30, 2010, or as soon as practicable thereafter. It is expected that a "D" will be appended to the Company's ticker symbol to indicate the completion of the Reverse Split and after a 20 trading-day period following the Reverse Split, the ticker symbol will revert to "HSKA". A new CUSIP number has been assigned to the Company's common stock as a result of the Reverse Split.

Heska's primary objective in effecting the Reverse Split, as set forth in detail in its Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on November 23, 2010 (File No.: 000-22427), is to increase the per share trading price of the issued and outstanding shares of common stock in order to regain and maintain long-term compliance with the minimum bid price listing requirements of The NASDAQ Capital Market.

TOZ

05/27/10 2:06 PM

Post #23

I am betting this stock sees a renewed interest. At least I am interested. Insiders still buying.

Camaro1093 Free

04/23/10 12:45 PM

Post #22

Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast

LOVELAND, Colo., April 23 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq:HSKA - News) announces the following Webcast:

What:
Heska Corporation Invites You to Listen to Its Annual Meeting of Stockholders on the Web

When:
Tuesday, May 4, @ 9:00 a.m. (MDT)

Where:
www.heska.com (click on the Annual Meeting of Stockholders link on the front page of this website)

How:
Live over the Internet -- Simply log on to the web at the address above.

Contact:
Contact – General Information: Yvonne Mulley, 970-493-7272 yvonne.mulley@heska.com

Media Contact: Jason Napolitano, 970-493-7272 jason.napolitano@heska.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

If you are unable to participate during the live webcast, the call will be archived at http://www.heska.com/ until May 18, 2010. To access the replay, click on the Annual Meeting of Stockholders link on the front page of this website.

Heska Corporation (NASDAQ:HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at http://www.heska.com/.

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/default.aspx and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webcastsupport@tfprn.com.)

Camaro1093 Free

03/04/10 3:25 PM

Post #21

Re: #19: @bfogerty - Hope $1 isn't a big psychological barrier!

Also, the Wall Street Analyst conf. they're presenting at on March 12 might possibly get some analysts initiating coverage w/ buy ratings, IMO.

GLTA.

Camaro1093 Free

03/04/10 12:51 PM

Post #20

Re: #19: @bfogerty - Hope $1 isn't a big psychological barrier!

It shouldn't take much buying to get over $1, IMO. Level 2 looks really thin.

GLTA.

bfogerty

03/04/10 12:49 PM

Post #19

Re: #18: @Camaro1093 - Might see $1 today, and if not, should

Hope $1 isn't a big psychological barrier!

Camaro1093 Free

03/04/10 12:37 PM

Post #18

Might see $1 today, and if not, should come tomorrow, IMO.

GLTA.

Camaro1093 Free

03/04/10 11:54 AM

Post #17

New 52wk high @ .96.

GLTA.

Camaro1093 Free

03/03/10 12:07 PM

Post #16

New 52wk high @ .92

GLTA.

Camaro1093 Free

03/03/10 12:03 PM

Post #15

Re: #14: @bfogerty - Hi Good to see some activity here. And good

IMO, it's due to people realizing that it's worth a lot more than .80. They are profitable as well. And, the presentations don't hurt much either.

GL.

bfogerty

03/02/10 8:13 PM

Post #14

Re: #12: @Camaro1093 - May make new day high soon, level 2

Hi
Good to see some activity here. And good to see the stock going up. Do you think this is all due to the announced presentations, or is something else going on?
fogerty

Camaro1093 Free

03/02/10 5:06 PM

Post #13

Heska to Present at The Wall Street Analyst Forum's 21st Annual Analyst Conference

LOVELAND, Colo., March 2 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq:HSKA - News) today announced it will present at The Wall Street Analyst Forum's 21st Annual Analyst Conference on Friday, March 12, 2010. The presentation will be at the University Club, 1 West 54th Street in New York City and is scheduled to begin at 2:20 p.m. Eastern Time (12:20 p.m. Mountain Time). The presentation will be available via live webcast and for two weeks following the presentation through a link on the investor relations portion of Heska Corporation's website.

(Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO)

About Heska

Heska Corporation (NASDAQ:HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Camaro1093 Free

03/02/10 3:45 PM

Post #12

May make new day high soon, level 2 looks thin.

GLTA.

Camaro1093 Free

03/02/10 11:56 AM

Post #11

Dir AYLESWORTH Buys 18,000 Of HESKA CORP >HSKA

SOURCE: Form 4

ISSUER: HESKA CORP
SYMBOL: HSKA

FILER: AYLESWORTH WILLIAM A
TITLE: Director

DATE TRANSACTION SHARES PRICE VALUE
2/26/10 Purchase 18,000 $0.71 $12,712

OWNERSHIP: 80,000 (Direct)

The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.

Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)

Click here to go to Dow Jones NewsPlus, a web front page of today's most
important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=aXDfCUdb1q9GLEHfSqdUXA%3D%3D. You can use
this link on the day this article is published and the following day.

(END) Dow Jones Newswires

03-02-10 1114ET

11:14 030210

Camaro1093 Free

03/01/10 5:14 PM

Post #10

Heska to Present at LDV Capital Management's Growth and Value Conference

Presentations are Scheduled for March 3rd and 4th

LOVELAND, Colo., March 1 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq:HSKA - News) today announced it will present at LDV Capital Management's Growth and Value Conference on March 3rd and 4th, 2010 at the Sheraton Suites Cypress Creek, 555 NW 62nd Street in Fort Lauderdale, FL. The presentation on both days is scheduled to begin at 5:30 p.m. Eastern Time.

About Heska

Heska Corporation (Nasdaq:HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Camaro1093 Free

03/01/10 12:45 PM

Post #9

Lots of insider purchases recently: http://www.filing4.com/company/symbol/?sym=hska

GLTA.

Camaro1093 Free

02/24/10 11:33 AM

Post #8

Here's a link to the 4Q earnings call: http://www.videonewswire.com/event.asp?id=66382

GLTA

Camaro1093 Free

02/24/10 11:32 AM

Post #7

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians.

Camaro1093 Free

02/24/10 11:31 AM

Post #6

Insider transactions: http://www.mffais.com/hska

Camaro1093 Free

02/24/10 11:31 AM

Post #5

Heska Announces Q4 and Annual 2009 Results

Heska Corporation (Nasdaq: HSKA, "Heska" or the "Company") today reported financial results for its fourth quarter and the year ended December 31, 2009.

"In the fourth quarter of 2009, we produced revenue growth in both of our operating segments, increased our gross margin and decreased our operating expenses compared to the fourth quarter of 2008. For full year 2009, our team generated over $4 million in operating income - the second best result in company history, despite a challenging economic environment," said Robert Grieve, Heska's Chairman and CEO. "We also placed our first DRI-CHEM(R) 7000 Veterinary Chemistry Analyzers with our customers in the fourth quarter of 2009. We have been pleased with customer interest in this fine new product, which represents a line extension in our chemistry offering and is the fastest multi-patient clinical chemistry analyzer available to the veterinary in-clinic market. We also are excited by the prospects for another new product in 2010, the VitalPath(TM) Blood Gas and Electrolyte Analyzer, which we expect to begin shipping to our customers in the near future."

Investor Conference Call

Management will conduct a conference call on Monday, February 22, 2010 at 1:00 p.m. MST (3:00 p.m. EST) to discuss the fourth quarter and year-end 2009 financial results. To participate, dial (877) 941-2333 (domestic) or (480) 629-9723 (international); the conference call access number is 4218183. The conference call will also be broadcast live over the Internet at http://www.heska.com. To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software. Telephone replays of the conference call will be available for playback until March 8, 2010. The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international). The webcast replay may be accessed from Heska's home page at www.heska.com until March 8, 2010.

About Heska

Heska Corporation (Nasdaq: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the access to products from Abbott Point of Care Inc. as of November 1, 2009, which represent approximately 15% of Heska's revenue for the year ended December 31, 2009, including the impact of the loss of related profits on Heska's year-over-year performance; risks inherent in relying on perceived initial customer interest to indicate future market acceptance and success of any given product; uncertainties related to product performance and market acceptance of any product planned, but not yet placed, with customers; risks related to any change in Heska's strategy, including Heska's recent decision to terminate its contractual agreements with most domestic third-party distributors who carry Heska's full product line, and the year-over-year and future impact of any such decision; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and whom may be large Heska customers; uncertainties regarding Heska's ability to successfully market and sell its products in an economically sustainable manner; risks related to Heska's reliance on third parties to properly and timely complete certain research and development activities; competition, including uncertainties regarding the impact of new products competitors have recently launched or may launch in the future; uncertainties related to Heska's ability to maintain its listing on the Nasdaq Capital Market; uncertainties regarding Heska's ability to generate profits and positive cash flow in future periods; risks regarding Heska's reliance on third-party suppliers, which is substantial and could have significant negative consequences if Heska were to lose access to a product line; uncertainties regarding overall economic conditions and the affect of these conditions on Heska's business, which may change as compared to historical results, as well as Heska's accuracy in predicting these and related matters; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2008 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2009.

Financial Table Follows:
View data

Consolidated Statements of Operations
In Thousands, Except per Share Amounts
(unaudited)

Three Months Twelve Months
Ended Ended
----- -----
December 31, December 31,
------------ ------------
2008 2009 2008 2009
---- ---- ---- ----
Revenue, net:
Core companion animal health $13,667 $14,541 $68,140 $66,449
Other vaccines, pharmaceuticals
and products 1,767 2,817 13,513 9,229
----- ----- ------ -----
Total revenue, net 15,434 17,358 81,653 75,678
------ ------ ------ ------

Cost of revenue 11,093 10,723 52,809 47,219
------ ------ ------ ------

Gross profit 4,341 6,635 28,844 28,459
----- ----- ------ ------

Operating expenses:
Selling and marketing 3,616 3,449 17,640 14,524
Research and development 489 410 1,951 1,718
General and administrative 2,161 1,918 8,917 8,173
Restructuring expenses 785 - 785 -
Other 232 - 232 -
--- --- --- ---
Total operating expenses 7,283 5,777 29,525 24,415
----- ----- ------ ------
Operating income (loss) (2,942) 858 (681) 4,044
Interest and other expense, net 140 113 640 306
--- --- --- ---
Income (loss) before income taxes (3,082) 745 (1,321) 3,738
Income tax expense (benefit) (1,215) 285 (471) 1,496
------ --- ---- -----
Net income (loss) $(1,867) $460 $(850) $2,242
======= ==== ===== ======

Basic net income (loss) per share $(0.04) $0.01 $(0.02) $0.04
====== ===== ====== =====
Diluted net income (loss) per share $(0.04) $0.01 $(0.02) $0.04
====== ===== ====== =====

Shares used for basic net income
(loss) per share 51,821 52,123 51,674 52,068
====== ====== ====== ======

Shares used for diluted net income
(loss) per share 51,821 52,199 51,674 52,115
====== ====== ====== ======

Balance Sheet Data
In Thousands (unaudited)

December 31, December 31,
2008 2009
---- ----
Cash and cash equivalents $4,705 $5,400
Total current assets 31,290 28,493
Total assets 70,438 64,134
Line of credit 11,042 4,201
Current portion of long-term debt 770 381
Total current liabilities 22,228 14,107
Long-term debt, net of current portion 381 -
Stockholders' equity 42,523 45,055

Consolidated Statements of Operations In Thousands, Except per Share Amounts (unaudited) Three Months Twelve Months Ended Ended ----- ----- December 31, December 31, ------------ ------------ 2008 2009 2008 2009 ---- ---- ---- ---- Revenue, net: Core companion animal health $13,667 $14,541 $68,140 $66,449 Other vaccines, pharmaceuticals and products 1,767 2,817 13,513 9,229 ----- ----- ------ ----- Total revenue, net 15,434 17,358 81,653 75,678 ------ ------ ------ ------ Cost of revenue 11,093 10,723 52,809 47,219 ------ ------ ------ ------ Gross profit 4,341 6,635 28,844 28,459 ----- ----- ------ ------ Operating expenses: Selling and marketing 3,616 3,449 17,640 14,524 Research and development 489 410 1,951 1,718 General and administrative 2,161 1,918 8,917 8,173 Restructuring expenses 785 - 785 - Other 232 - 232 - --- --- --- --- Total operating expenses 7,283 5,777 29,525 24,415 ----- ----- ------ ------ Operating income (loss) (2,942) 858 (681) 4,044 Interest and other expense, net 140 113 640 306 --- --- --- --- Income (loss) before income taxes (3,082) 745 (1,321) 3,738 Income tax expense (benefit) (1,215) 285 (471) 1,496 ------ --- ---- ----- Net income (loss) $(1,867) $460 $(850) $2,242 ======= ==== ===== ====== Basic net income (loss) per share $(0.04) $0.01 $(0.02) $0.04 ====== ===== ====== ===== Diluted net income (loss) per share $(0.04) $0.01 $(0.02) $0.04 ====== ===== ====== ===== Shares used for basic net income (loss) per share 51,821 52,123 51,674 52,068 ====== ====== ====== ====== Shares used for diluted net income (loss) per share 51,821 52,199 51,674 52,115 ====== ====== ====== ====== Balance Sheet Data In Thousands (unaudited) December 31, December 31, 2008 2009 ---- ---- Cash and cash equivalents $4,705 $5,400 Total current assets 31,290 28,493 Total assets 70,438 64,134 Line of credit 11,042 4,201 Current portion of long-term debt 770 381 Total current liabilities 22,228 14,107 Long-term debt, net of current portion 381 - Stockholders' equity 42,523 45,055

SOURCE Heska Corporation

t-41

06/07/08 11:25 PM

Post #4

Hello!

mitcheroo

10/23/06 11:06 AM

Post #3

Looks like it might be bouncing off the 50dma today. Under very strong accumulation, per IBD. 3Q results are due within the next few weeks.

AirPocketDrop___YES Terminated

01/31/06 1:19 PM

Post #2

Re: #1: @onthetake - Hey there APD, just wanted to get the

Heska is a pet medicine company.

I have no position in the company.

The company was profitable last quarter for the first time in close to a decade. Rev. at $19 million, +2.8 million over the recent quarter. Management promised a profitable quarter and delivered on it. The stock was facing a potential delisting by not meeting exchange requirements. Animal healthcare and products are growing as Americans spend more on their pets.

onthetake

01/30/06 2:46 PM

Post #1

Hey there APD, just wanted to get the first message here. LOL

SO what is the deal with Heska??

OTT

Heska Corporation (HSKA)

Followers	6	Posters	16
Posts (Today)	0	Posts (Total)	36
Created	07/26/05	Type	Free
Moderators

Discuss Heska Corporation. > > SEC Filings http://www.sec.gov/cgi-bin/browse-edgar?company=Heska&CIK=&filenum=&State=&SIC=&.... Income Statement http://finance.yahoo.com/q/is?s=HSKA Balance Sheet http://finance.yahoo.com/q/bs?s=HSKA Statement of Cash Flow http://finance.yahoo.com/q/cf?s=HSKA